<DOC>
	<DOC>NCT02558413</DOC>
	<brief_summary>This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1 clinical trial to determine the safety and tolerability of BTA-C585 administered orally to healthy subjects.</brief_summary>
	<brief_title>Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy men and women aged 1860 years; Weight â‰¥ 50 kg and Body Mass Index (BMI) of 19 to 32; Female subjects must be of nonchildbearing potential; Male subjects must agree to use a double barrier method of birth control; Able to provide informed consent Current or recent (within 14 days of Day 0) bacterial or viral infection; Positive results for hepatitis B, hepatitis C, or HIV; Clinically significant abnormalities noted on ECG; Safety laboratory abnormalities; Regular use of medications, prescription or nonprescription; Poor vein access or fear of venipuncture; Major surgery, significant recent injury or trauma within 30 days; Received an investigational drug or vaccine within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Viral Diseases</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Paramyxoviridae Infections</keyword>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>Aviragen Therapeutics, Inc.</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>